로딩 중…
지수 로딩 중…
GeneOne Life Science, Inc.
011000· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩694-17.67%
2026-06-19
Price Chart
GeneOne Life Science, Inc.-73.91%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 63.07B KRW |
| Revenue | 17.12B KRW |
| Net Income | -45.40B KRW |
| Total Assets | 131.29B KRW |
| Net Assets | 51.15B KRW |
| Employees | 44 |
| Value | |
| P/B | 1.23x |
| P/S | 3.68x |
| FCF Yield | -26.23% |
| Profitability | |
| ROE | -88.74% |
| ROA | -34.58% |
| Op. Margin | -217.93% |
| Revenue Growth | -69.65% |
| Financial Health | |
| Debt Ratio | 256.65% |
| Total Debt | 30.50B KRW |
| FCF | -16.54B KRW |
| Cash | 5.30B KRW |
| Current Ratio | 0.46x |
| Performance | |
| 1Y Return | -73.91% |
| 1M Return | -57.53% |
| From 52W High | -76.98% |
| 1Y MDD | -81.53% |
| Trading | |
| Volume | 4,891,771 shares |
| Foreign Own. | 1.77% |
| Per Share | |
| EPS | -533 KRW |
| BPS | 564 KRW |
Company Info
Geneone Lifescience, established in 1976 for the manufacturing and sales of apparel interlining, was listed on the stock market in 1987 and operates local subsidiaries in the United States and Vietnam. The company is developing biopharmaceutical CDMO business and new biopharmaceutical drugs, with a focus on SFTS and COVID-19 DNA vaccines, and novel anti-inflammatory therapeutics. Leveraging its nucleic acid-based vaccine platform technology, it received invitations to the World Vaccine Congress Asia in 2023 and 2024, and was awarded the Grand Prize in Korea's promising vaccine sector. Geneone Lifescience is headquartered in Yeongdeungpo-gu, Seoul Metropolitan City.